Scarica l'app Stockscreener
26.87
3.15%
-0.8822
Uniqure Nv Borsa (QURE) Ultime notizie
RTW Investments and R. Wong report 2.59M shares in uniQure (NASDAQ: QURE) - Stock Titan
What Just Happened with uniQure's Earnings and FDA Update - Kavout
UniQure NV (QURE) price target decreased by 26.57% to 37.82 - MSN
uniQure N.V. (NASDAQ: QURE) Long Term Investor Alert: Investigation of potential Wrongdoing - openPR.com
Makary exit may temporarily lift biotech sentiment but FDA leadership vacuum looms - marketscreener.com
Is uniQure N.V. (QURE) A Good Stock To Buy Now? - Insider Monkey
Uniqure Insider Sold Shares Worth $1,127,500, According to a Recent SEC Filing - marketscreener.com
uniQure (QURE) CMO sells 45,000 shares under 10b5-1 plan, exercises options - Stock Titan
State Street (QURE) affiliates disclose 3.6% ownership, 2.26M shares - Stock Titan
UniQure Q1 Earnings Review: Limited Progress With FDA, But UK Approval In Play - Seeking Alpha
FDA's Makary On Brink: Why Biotech And Pharma Investors Shouldn't Panic (Or Celebrate) - Seeking Alpha
uniQure NV(QURE) Stock Options Chain | Quotes & News - Moomoo
UniQure (QURE) files Form 144: 45,000 shares, vested and exercised stock listed - Stock Titan
uniQure N.V.Ordinary Shares (NQ: QURE - FinancialContent
uniQure N.V. (NASDAQ:QURE) Just Reported And Analysts Have Been Cutting Their Estimates - simplywall.st
uniQure N.V. (NASDAQ:QURE) Consensus Forecasts Have Become A Little Darker Since Its Latest Report - Yahoo Finance
UniQure plans UK AMT-130 MAA submission in Q3 as it expects cash runway into H2 2029 - MSN
uniQure N.V. (QURE) Stock Analysis: A Potential Upside of 64% Amidst Promising Gene Therapy Innovations - DirectorsTalk Interviews
(QURE) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily
UniQure (QURE) Q1 2026 Loss Of US$53.5m Tests Bullish Growth Narrative - Sahm
RBC Capital Maintains UniQure NV(QURE.US) With Buy Rating, Maintains Target Price $35 - 富途牛牛
H.C. Wainwright Maintains UniQure NV(QURE.US) With Buy Rating, Cuts Target Price to $50 - 富途牛牛
A Quick Look at Today's Ratings for UniQure NV(QURE.US), With a Forecast Between $25 to $37 - Moomoo
uniQure NV | SCHEDULE 13G/A: Others - Moomoo
FMR LLC lists 1.74M UNIQURE shares (2.8%) — UNIQURE (NASDAQ: QURE) - Stock Titan
Transcript: uniQure Q1 2026 Earnings Conference Call - Sahm
MSN Money - MSN
Stifel Maintains UniQure NV(QURE.US) With Buy Rating, Announces Target Price $28 - 富途牛牛
TD Cowen Maintains UniQure NV(QURE.US) With Buy Rating - 富途牛牛
Uniqure NV at TD Cowen Healthcare Conference Transcript - GuruFocus
uniQure Q1 Earnings Call Highlights - Yahoo Finance
UniQure N.V. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
uniQure Releases Q1 2026 Financial Results - AlphaStreet
UniQure Shares Fall After Q1 Loss Widens - marketscreener.com
QURE: AMT-130 advances toward U.K. MAA, revenue rises, and cash runway extends into H2 2029 - TradingView
UniQure 1Q Loss/Shr 85c >QURE - Moomoo
Uniqure NV reports results for the quarter ended March 31Earnings Summary - TradingView
QURE Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
uniQure upgraded by RBC Capital Mkts with a new price target - Quantisnow
Q1 2026 Uniqure NV Earnings Call Transcript - GuruFocus
uniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates - Yahoo Finance
Earnings Flash (QURE) UniQure Posts Q1 Net Loss $0.85 a Share, vs. FactSet Est of $0.85 Loss - marketscreener.com
Earnings Flash (QURE) uniQure N.V. Reports Q1 Revenue $3.6M, vs. FactSet Est of $5.2M - marketscreener.com
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates - The Manila Times
UniQure: Q1 Earnings Snapshot - Barchart.com
uniQure N.V. 1Q 2026: Revenue $3.56M, Net income ($53.54M), EPS ($0.85) — 10-Q Summary - TradingView
[10-Q] uniQure N.V. Quarterly Earnings Report - Stock Titan
uniQure targets UK filing for AMT-130 as FDA seeks new trial plan - Stock Titan
uniQure (NASDAQ: QURE) Q1 2026 loss widens, holds $586.6M cash runway - Stock Titan
Press Release: UniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates - Moomoo
uniQure’s AMT-130 Regulatory Progress Sharpens Huntington’s Disease Investment Case - Yahoo Finance
US-listed shares of uniQure NV rise nearly 20% - marketscreener.com
UniQure plummets as FDA calls for phase 3 trial for Huntington's asset AMT-130 - MSN
QURE stock just shot up 8%uniQure’s much-talked-about Huntington’s disease therapy gets a UK boost - MSN
Jennison Associates LLC Boosts Stake in uniQure N.V. $QURE - MarketBeat
uniQure advances AMT-130 toward UK marketing approval - The Globe and Mail
Update: UniQure Shares Rise After Firm Plans to Submit UK Marketing Application for Huntington's Disease Treatment - 富途牛牛
Chardan Capital Maintains UniQure NV(QURE.US) With Buy Rating, Raises Target Price to $37 - Moomoo
symbol__ Stock Quote Price and Forecast - CNN
uniQure (QURE) Shares Surge 22% on Positive Regulatory News for AMT-130 - GuruFocus
UniQure Plans to Submit UK Marketing Authorization Application for Huntington's Disease Treatment - Moomoo
0.44%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):